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Abstract
Combined methylmalonic acidemia (MMA) and homocysteinemia are a group of autosomal recessive disorders
caused by inborn errors of cobalamin metabolism, including CblC, D, F, and J, with cblC being the most common
subtype. The clinical manifestations of combined MMA and homocysteinemia vary, but typically include neurologic,
developmental and hematologic abnormalities.
We report 4 children with combined MMA and homocysteinemia who presented predominantly with late-onset
diffuse lung diseases (DLD). Of these, 3 accompanied by pulmonary arterial hypertension (PAH), 1 accompanied by
hypertension, and 2 accompanied by renal thrombotic microangiopathy (TMA), which was confirmed by renal
biopsy. This confirms combined MMA and homocysteinemia should be considered in the differential diagnosis of
DLD with or without PAH or renal TMA.
Keywords: Methylmalonic acidemia, Homocysteinemia, Homocystinuria, Diffuse Lung disease, Hypertension arterial
pulmonary, Children
Letter to the editor
In adults, it is reported that isolated hyperhomocysteine-
mia may damage blood vessels, causing pulmonary arterial
hypertension (PAH) and/or pulmonary thromboembolism
[1, 2]. Both microangiopathy and thromboembolism can
be the underlying mechanisms for pulmonary hyperten-
sion in CblC deficiency [3–8], but an association between
MMA and/or homocysteinemia and diffuse lung disease
(DLD) has not been broadly reported.
Here, we report a series of 4 pediatric patients with
combined MMA and homocysteinemia who developed
late-onset DLD. Of these, 3 presented with concomitant
PAH, 1 presented with concomitant hypertension, and 2
presented with concomitant renal thrombotic microan-
giopathy (TMA), which was confirmed by renal biopsy.
The main novelty of these cases was the predominantly
pulmonary symptomatology at presentation (i.e., chronic
wet cough or respiratory failure), with or without PAH
(as in the first episode of “pneumonia” or “asthma” of
patient 1, 3 and 4), the HRCT imaging findings, and the
lack of typical neurological sequelae and ophthalmological
findings. We speculate that pulmonary microangiopathy
secondary to combined MMA and homocysteinemia was
the primary cause of DLD in all 4 cases. Therefore, com-
bined MMA and homocysteinemia should be considered
in the differential diagnosis of DLD with or without PAH
or renal TMA. This diagnosis should be investigated
promptly with the proper metabolic investigations (total
plasma homocysteine, plasma acylcarnitine and urine or-
ganic acid profiles), so that treatment can be initiated in a
timely fashion, as lung disease secondary to this metabolic
disorder will respond to appropriate treatment but may
not respond to symptomatic treatment.
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A 21-month-old girl was transferred to our department
with a 6-month history of slight productive cough and a
2-month history of shortness of breath. She had previ-
ously been treated with intermittent antibiotics but the
cough was not resolved. Two months before admission,
she had developed shortness of breath and fever, and
been diagnosed with pneumonia. Echocardiography showed
mild tricuspid and pulmonary valve regurgitation with a tri-
cuspid regurgitation pressure gradient (TRPG, an estimate
of pulmonary artery pressure) of 26 mmHg, which sug-
gested that pulmonary artery (PA) pressure was normal.
High-resolution computed tomography (HRCT) showed
diffuse interstitial pneumonia, consolidation and pleural ef-
fusions. Fever, pulmonary consolidation and pleural effu-
sions were resolved after treatment with antibiotics and
glucocorticoids at her local hospital, but her shortness of
breath and productive cough got worse.
On admission to our hospital, the patient was dyspneic,
with nasal alar flaring and retraction, cyanosis in the lips
and nail beds. There were no rales or cardiac murmurs on
auscultation of the chest. The laboratory investigations
showed a white blood cell count of 14,090/mL with 66.6%
neutrophils, hemoglobin (Hb) 9.8 ~ 12.6 g/dL, platelet
322 ~ 387 × 109/L, serum lactate dehydrogenase (LDH)
563 IU/L and indirect bilirubin (IBIL) 33.5 μmol/L; and
normal serum C-reactive protein concentration and renal
function. The urinalysis showed protein in urine ranging
from negative to 2+ and red blood cells (RBCs) from 0 ~
2/HP to 2 ~ 6/HP. Arterial blood gas analysis showed type
1 respiratory failure and a mild metabolic acidosis.
Sputum cultures were negative for bacterial, fungal and
mycobacterial infection. An HRCT scan of her chest
showed diffuse ground-glass opacification in the lower
regions of the lungs, areas of smooth thickening of the
interlobular septum and increased PA diameter (Fig. 1a).
Echocardiography showed moderate PAH (TRPG 68 mmHg)
with moderate dilation of the right atrium and ven-
tricle, mild tricuspid and pulmonary valve regurgitation,
and an ejection fraction (EF) of 74%. Based on the bilateral
diffuse lung lesion of unknown reasons, mild metabolic
acidosis, and her low BMI, we suspected she suffered from
metabolic disease. Laboratory testing showed elevated
concentration of methylmalonic acid in the serum
(0.218 mg/dL) and urine (0.428 mg/dL, >420 times the
reference value), and a high plasma homocysteine (Hcy)
concentration (>50.0 μmol/L, reference range 5~15 μmol/L).
Magnetic resonance imaging (MRI) of the brain was
performed, which revealed dilated lateral ventricles with
mild hydrocephalus, although she had no sigh of
neurologic abnormalities. Genetic analysis confirmed a
compound heterozygosity in MMACHC, with c.80A >
G(p.Q27R) and c.331C > T(p.R111Ter) sequence vari-
ants, inherited from the patient’s mother and father,
respectively. Combined MMA with homocysteinemia,
CblC type/CblC defect/CblC deficiency was confirmed.
At diagnosis on day 7 of her admission to our hospital,
treatment with captopril (3.125 mg twice daily orally)
and vitamin B12 (cyanocobalamin, 0.5 mg daily intra-
muscularly) was started. She had improved significantly
by day 10. On day 13, we added folate (5 mg once daily
orally), betaine (250 mg/kg once daily orally), levocarni-
tine (100 mg/kg once daily orally) and vitamin B6
Fig. 1 Lung CT showing the presence in both lungs of 1a diffuse ground-glass opacification predominant in lower region of lung and areas with
smooth thickening of interlobular septum (on admission; Patient 1), 1b absence of abnormal pulmonary feature(after 1 month of treatment; Patient 1),
2a interlobular septal thickening and bilateral pleural effusion (1 year before admission; Patient 2), 2b diffuse poorly defined centrilobular nodules(5 days
after treatment; Patient 2), 2c pulmonary artery (PA) with an enlarged diameter exceeding the aorta(5 days after treatment; Patient 2), and 3 diffuse
poorly defined ground-glass centrilobular nodules(on admission; Patient 3)
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(10 mg/kg twice daily orally) to her therapeutic regime.
Her symptoms improved gradually. One month later,
HRCT of the lung showed significant improvement
(Fig. 1b), but she continued to require intermittent low-
flow supplemental oxygen for a further 4 months. At
follow-up 1 year later, echocardiography found normal
PA pressures and lung CT findings were normal. She
was asymptomatic at 3 years’ follow-up.
Patient 2
A girl aged 4 years and 7 months presented with a 1-year
history of slight cough and shortness of breath. She had
been observed to have lower than expected levels of phys-
ical activity, and slightly delayed intellectual and language
development since birth. Echocardiography and MRI of
the brain undertaken when she was 1 year old had been
normal. She had been admitted to her local hospital 1 year
previously due to bilateral palpebral edema, and slight
cough and shortness of breath. Echocardiography under-
taken at the time showed PAH, blood routine test showed
a hemoglobin level of 7.7 g/dL and a platelet count of
161 × 109/L, urinalysis showed proteinuria (2+) and
microscopic hematuria, and HRCT showed interlobular
septal thickening and bilateral pleural effusions (Fig. 1c).
After treatment with bosentan, a diuretic and captopril,
the palpebral edema, proteinuria and pleural effusions re-
solved gradually, but her cough, dyspnea and PAH did not
improve, and HRCT revealed multiple nodular lesions in
both lungs, so she was referred to our department.
On admission to our hospital, physical examination re-
vealed she had cyanosis of the lips and nail beds. Chest
auscultation revealed a second-degree systolic heart
murmur but no rales in the lungs. Laboratory investiga-
tions detected increased serum LDH (384 IU/L) and
blood urea nitrogen (BUN) concentration (11.64 mmol/
L, normal range 1.7~ 7.1 mmol/L). Urinalysis revealed
protein in urine 2+ and RBCs ranging from 0 ~ 2/HP to
4 ~ 6/HP. We undertook metabolic studies for her slight
development delay and renal injury. Methylmalonic acid
concentrations were elevated in the serum (0.294 mg/dL)
and urine (0.354 mg/dL, >350 times the reference value),
and a plasma Hcy concentration was >50.0 μmol/L.
Therefore ophthalmologic examination was performed,
which revealed bilateral macular coloboma. Echocardi-
ography showed severe PAH (TRPG 81 mmHg) with
moderate dilation of the right atrium and ventricle, EF
68%, moderate tricuspid regurgitation and mild pul-
monary regurgitation. Her parents did not consent to
her undergoing genetic testing. Combined MMA with
homocysteinemia was clinically diagnosed.
After diagnosis on day 5 of her admission to our hos-
pital, she was started on treatment with parenteral
cyanocobalamin, levocarnitine, vitamin B6 and betaine.
Her symptoms improved gradually. On day 10, contrast-
enhanced lung CT showed diffuse poorly defined centri-
lobular nodules, and dilation of the PA to a diameter ex-
ceeding that of the aorta (Fig. 1d, e). By day 13, she was
more active and was able to get out of bed. On day 15,
oxygen treatment was discontinued. On day 22, echo-
cardiography showed mild to moderate PAH (TRPG
60 mmHg) with mild dilatation of the right atrium and
ventricle, mild tricuspid regurgitation and mild pulmonary
regurgitation. At follow-up 2 months later at her local
hospital, lung CT and echocardiography showed further
substantial improvements. Unfortunately, she died sud-
denly 6 months later without an autopsy.
Patient 3
A girl aged 8 years and 5 months was admitted to our
hospital for investigation after a 6-year history of de-
creased activity and intermittent vomiting and diarrhea,
and a 2-year history of renal impairment and slight
productive cough. Two years before admission, she had
been diagnosed with renal failure, hypertension and mod-
erate anemia. Based on her clinical characteristics, she was
suspected of having Goodpasture syndrome or vasculitis
at her local hospital. At that time, urinalysis showed pro-
teinuria 2+ and microscopic hematuria, and the lung CT
revealed diffuse interstitial and parenchymal infiltration.
On admission to our hospital, physical examination re-
vealed she had mild cyanosis of the nail beds. There
were no rales or heart murmurs on auscultation of the
chest. In laboratory investigations she had elevated BUN
(7.73 mmol/L), serum creatinine (115 μmol/L) and IBIL
(21.9 μmol/L) concentrations. Routine blood tests showed
low hemoglobin (9.6 ~ 11.5 g/dL) without thrombocytopenia.
The urinalysis revealed protein in urine ranging from
negative to 2+ and RBCs from 0 ~ 2/HP to 2 ~ 4/HP.
Diffuse poorly defined ground-glass centrilobular nodules
were seen on HRCT (Fig. 1f ). Echocardiography was
normal, with no evidence of PAH. We undertook meta-
bolic studies for her renal failure of unknown reasons.
Methylmalonic acid concentration in the serum was
0.299 mg/dL and in the urine was 0.127 mg/dL (>120
times the reference value); plasma Hcy concentration
was >50.0 μmol/L. Therefore brain MRI was performed,
which revealed evident demyelinating lesions, although
she had no sign of neurologic abnormalities. Genetic ana-
lyses confirmed a compound heterozygosity in MMACHC,
with c.80A > G(p.Q27R) and c.609G > A(p.W203X) se-
quence variants, inherited from the patient’s mother
and father, respectively. Mutation screening of atypical
hemolytic uremic syndrome (HUS) associated genes
(CFHR1, CFHR3, CFH, CD46, CFI, CFB, C3 and THBD),
PAH associated genes (SMAD9, CAV1, KCNK3, CTEPH1,
CPS1 and SARS2), pulmonary venous occlusive disease
(PVOD) and pulmonary capillary hemangiomatosis
(PCH) associated genes (BMPR2, EIF2AK4) showed no
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abnormalities. Combined MMA with homocysteinemia,
CblC type was confirmed.
On day 1 after admission, she was treated with oral
amlodipine besylate and fosinopril. On day 6, after diag-
nosis, treatment with parenteral cyanocobalamin, folate,
levocarnitine, vitamin B6 and betaine was initiated.
Renal biopsy undertaken on day 7 subsequently revealed
mesangioproliferative glomerulonephritis and TMA with
stenotic and occlusive capillaries and ischemic sclerosis.
By day 10, her physical strength was improving. On day
11, bronchoscopy was performed and there was no evi-
dence of hemosiderin-laden alveolar macrophages in the
bronchoalveolar lavage fluid (BALF). She improved sig-
nificantly at 9 months’ follow-up.
Patient 4
A boy aged 7 years and 8 months was referred to our re-
spiratory department because of a month period of mild
wet cough particularly in the morning and shortness of
breath. The HRCT showed mild diffuse ground-glass
opacification in both lungs. Echocardiography revealed
severe PAH. Asthma was suspected. After receiving a
treatment with montelukast and repeated antibiotics for
1 month, and sildenafil and captopril for 15 days, his
shortness of breath and PAH (mild to moderate) dra-
matically improved, but the cough was not resolved.
When he was 4 months of age, he had hemolytic anemia
without thrombocytopenia or kidney damage. Addition-
ally, he had been diagnosed with acute glomeruloneph-
ritis with mild microscopic hematuria 1 year earlier.
On admission to our department, physical examin-
ation revealed no rales or heart murmurs on ausculta-
tion of the chest. We highly suspected he had combined
MMA with homocysteinemia. Laboratory investigations
showed a hemoglobin of 10.4 g/dL and mildly elevated
LDH (330 IU/L), BUN (9.67 mmol/L), and Cr (71 μmol/L).
Urinalysis only revealed sparse RBCs. Blood smear examin-
ation revealed sparse fragmented and deformed RBC. The
serum and urinary methylmalonic acid concentrations
were 0.383 mg/dL and 0.1034 mg/dL (>103 times the
reference value) respectively, and plasma Hcy concen-
tration was 193.76 μmol/L. Brain MRI revealed evident
demyelinating lesions, although he had no sign of
neurologic abnormalities. Genetic analyses confirmed a
compound heterozygosity in MMACHC, with c.80A >
G(p.Q27R) and c.609G >A(p.W203X) sequence variants,
inherited from the patient’s father and mother, respect-
ively. Mutation screening of atypical HUS and PAH asso-
ciated genes showed no abnormalities. Combined MMA
with homocysteinemia, CblC type was confirmed.
After admission, he was continuously treated with oral
sildenafil and captopril. On day 4, treatment with parenteral
cyanocobalamin, folate, levocarnitine, vitamin B6 and beta-
ine was initiated. Renal biopsy undertaken on day 6
subsequently revealed TMA with stenotic capillaries, ische-
mic sclerosis, and membranoproliferative glomeruloneph-
ritis. Transbronchoscopic lung biopsy undertaken on day 9
subsequently revealed a thickening of the alveolar septum
with a small quantity lymphatic tissue and lymphocytes.
There was no evidence of hemosiderin-laden alveolar mac-
rophages in the BALF. On day 15, his cough improved sig-
nificantly and echocardiography just showed mild PAH.
In all 4 patients, metabolic investigations were suggestive
of cobalamin deficiency, with elevated blood propionylcar-
nitine (C3) concentration as well as an elevated propionyl-
carnitine–acetylcarnitine (C3/C2) ratio, in the context of
low or normal concentrations of methionine. Clinical
characteristics and results of auxiliary examination of the 4
patients are summarized in Tables 1, 2 and 3.
Discussion
In this case series of children with combined MMA and
homocysteinemia presenting predominantly with late-onset
DLD, 3 cases also had PAH and 1 had hypertension. The
diagnosis was made in each of the patients mainly on the
basis of clinical features of multisystem damage, elevated
serum and urine methylmalonic acid concentrations, ele-
vated plasma homocysteine concentration, and elevated
blood C3 concentration and C3/C2 ratio. Combined MMA
with homocysteinemia results from deficient synthesis of
the coenzymes derived from vitamin B12. So far, eight vari-
ants have been described, cobalamin C (CblC) being the
most prevalent. The Cb1C defect was confirmed in patients
1 (c.80A >G, c.331C >T), 3(c.80A >G, c.609G >A) and 4
(c.80A >G, c.609G >A). Patient 2 had macular coloboma,
which is supportive of a cblC defect, however her parents
refused to give consent for the genotyping analysis. All 3
patients carried the c.80A >G mutation which has been re-
ported in 4 Chinese patients with TMA or PAH [9]. The
c.331C >T mutation was associated with the early-onset
form mainly in the French, Canadian, Acadian and Cajun
populations [10, 11], and has been reported in 1 Chinese
patient [12]. The c.609G >A mutation is a hot spot muta-
tion in Chinese patients with CblC defect [12, 13] and has
been reported in 2 Chinese patients with HUS [14]. Patient
3 and 4 carried compound heterozygous mutations
(c.80A >G, c.609G >A), which have been reported in eight
Chinese patients with early-onset of the condition [12, 13],
and 1 late-onset Chinese patient with PAH and renal TMA
[9]. However, to date, the most frequent MMACHC muta-
tions associated with PAH and renal TMA were
c.271dupA, c.276G >T, and c.565C >A in Western coun-
tries [4–7, 15, 16].
Combined MMA and homocysteinemia is a multisyste-
mic disorder that can lead to damage to the central nervous
system, retina, liver, kidneys and bone marrow (http://
www.ncbi.nlm.nih.gov/books/NBK1328/). In our series, all
patients had evidence of renal injury, hematologic and
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neurologic abnormalities to some extent;patient 2 also
had bilateral macular coloboma, which are also com-
mon in combined MMA and homocysteinemia. Car-
diomyopathy, both dilated, hypertrophic and non
compaction, as well as microangiopathy have been de-
scribed in patients affected with this group of condi-
tions [17]. There have been 2 reports of pulmonary
embolism and PAH in children with cobalamin C de-
fect [3, 18], 7 of PAH in patients(including 1 adult)
with cobalamin C defect [4–7, 9, 15, 16], 1 of PAH in
newborn with MMA [19]. PVOD has been described
as histological diagnosis in 3 patients with CblC
defect [6, 16]. Contrast-enhanced lung CT was
performed in patient 2 and didn’t show thin pulmon-
ary venous or pulmonary artery embolism. DLD im-
proved significantly after treatment in all patients,
which didn’t suggest PVOD. In addition the lung
abnormalities identified on imaging were not suffi-
ciently severe to have caused PAH. Therefore we con-
sider PAH was caused by combined MMA and
homocysteinemia.
In this study, we aimed to show that there may be a
relationship between combined MMA and homocystei-
nemia and DLD in children, although interstitial lung
disease has been reported in association with other syn-
dromes such as Niemann-Pick disease, as well as pul-
monary alveolar proteinosis. No other causes of DLD,
such as connective tissue disease, alveolar hemorrhage
syndromes, pulmonary vasculitis, hypersensitivity pneu-
monitis, drug induced interstitial pneumonia, or infec-
tion were detected in any of the patients. Thus we think
that in these cases, it is highly possible that DLD was
caused by combined MMA and homocysteinemia, and
not by PAH, based on the following reasons. Respiratory
Table 2 Laboratory features of 4 Chinese patients with combined MMA and homocysteinemia
Patient 1 Patient 2 Patient 3 Patient 4
Hemoglobin(g/dL) 9.8 ~ 11.6 11.5 ~ 12.5 9.6 ~ 11.5 104
MCV(fL) 113.4 ~ 118.6 91.3 ~ 92.5 89.4 ~ 94.6 103.8
Platelet(×109/L) 322 ~ 387 161 ~ 317 249 ~ 332 502
Urine protein Negative ~ 2+ 2+ Negative ~ 2+ Negative
Urinary erythrocytes 0-2/HP ~ 2-6/HP 0-2/HP ~ 4-6/HP 0-2/HP ~ 2-4/HP sparse
Arterial blood gas analysis PaO2: 27 mmHg, mild
metabolic acidosis
PaO2: 49 mmHg PaO2: 60 mmHg PaO2: 83 mmHg
Liver function,serum albumin,
cholesterol, triglyceride
Normal Normal Normal Normal
IBIL (μmol/L) 33.5 10.5 21.9 8.69
BUN(mmol/L) 7.1 12.37 BUN7.73 BUN9.67
Cr (μmol/L) 38 67 115 71
eGFR (80–120 mL/min/1.73 m2) 81 61 37 64
Serum LDH(IU/L) 563(normal range:50 ~ 240) 384(normal range:50 ~ 240) 286(normal range:110 ~ 295) 330((normal range:
110 ~ 295)
Methionine concentrations
(normal range:8.6 ~ 23.3 μmol/L)
7.6 22.6 8.4 11.1
Serous vitamin B12 Normal Normal Normal Normal
Serous folate Normal Normal Normal Normal
Complement C3,C4 Normal Normal Normal Normal
Thyroid hormones Normal Normal Normal Normal
Immune globulin Normal Normal Normal Normal
Lymphocyte subsets Normal Normal Normal Normal
Serum ceruloplasmin Normal Normal Normal Normal
ANA,dsDNA,ACA, ANCA Negative Negative Negative Negative
Anti-GBM Ab Negative Negative Negative Negative
Coombs test Negative Negative Negative ±
Bone marrow examination Megaloblastic anemia Normal Megaloblastic anemia Normal
Abbreviations: ANA antinuclear antibody; ACA anticardiolipin antibody; ANCA antineutrophil cytoplasmic antibody; anti-GBM Ab-Anti-glomerular basement membrane
antibody; BUN blood urea nitrogen; Cr creatinine; dsDNA double stranded DNA antibody; eGFR estimated glomerular filtration rate; LDH lactate dehydrogenase;
IBIL indirect bilirubin concentration; MCV Mean Corpuscular Volume
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symptoms arose before or at the time of PAH diagnosis
in the first 2 patients and in patient 4. Additionally,
DLD existed in the absence of PAH in patient 3, despite
lung imaging being similar to that in patient 2. Further-
more, DLD improved substantially in all patients when
they were treated for MMA and homocysteinemia, but
patient 2 did not improve when she was treated with
bosentan.
Post mortem examination of 4 patients with combined
MMA and homocysteinemia found severe vascular le-
sions, with renal damage characteristic of TMA [20, 21],
thromboemboli in the pulmonary circulation [18, 21],
and massive endothelial proliferation in pulmonary post-
capillary venules [16]. In the renal biopsy undertaken in
the last 2 patients we observed TMA with stenotic and
occlusive capillaries. Further, there have been reports
showing this association [6, 7, 15, 16]. Additionally, the
first 2 patients also had renal injury (including protein-
uria and microscopic hematuria) and anemia. Further-
more patient 1 had an elevated level of serum LDH and
IBIL, and patient 2 had an elevated level of serum LDH,
which suggested that both of them might have atypical
renal TMA especially patient 1. Renal TMA may be
underestimated especially in China because its features
are too subtle. None of the 4 patients presented with
thrombocytopenia, which was consistent with the report
by Komhoff M [6]. There was also imaging evidence of
diffuse pulmonary microangiopathic lesions in all 4 of our
patients. Therefore, we also speculate that the damage
of vascular endothelial cell function (including pulmon-
ary vessels) was triggered by intracellular and systemic
changes by MMACHC variants. This was particularly
marked in the presence of increased serum homocyst-
eine concentration and could increase the permeability
of pulmonary capillaries. The resulting vasoconstric-
tion, vascular smooth muscle cell proliferation, and
microthrombus formation, especially pulmonary TMA
[1, 7], caused the presence of diffuse ground-glass opa-
cification and centrilobular nodules in the lungs.
In this paper, DLD was diagnosed by lung imaging.
DLD is consist of many kinds of lung diseases, including
pulmonary vasculopathy.
Our study has several limitations. We did not under-
take blood smear examination in the first 3 patients, be-
cause of our poor awareness of TMA. Additionally, we
did not undertake lung biopsy in the first 3 patients, as
it was not warranted by the severity of patients 1 and 2,
and the parents of patient 3 declined to give consent.
Patient 4 underwent transbronchoscopic lung biopsy,
and the histologic findings only showed a thickening of
the alveolar septum without vascular structure, owing to
the small tissue sample. These patients were not treated
with hydroxocobalamin, which was unavailable in main-
land China. We used TRPG to estimate PA pressures
rather than undertake right heart catheterization, which
is substantially more invasive.
Conclusions
CblC defect has biochemical (combined MMA and
homocysteinemia), radiological (DLD) and cardiological
(PAH) characteristics. Our study suggested combined
MMA and homocysteinemia be considered a potential
reversible cause of DLD and PAH. Prompt recognition,
diagnosis and treatment of CblC defect may reverse not
only lung damage, but may prevent other complications
associated with CblC defect (renal microangiopathy),
and that it should be suspected not only in children, but
in adults with similar findings.
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